Montag & Associates’s Cytokinetics CYTK Stock Holding History

Montag & Associates’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6	Closed	-$330	–	1015
2025 Q3	$330	Buy	+6	New	+$247	﹤0.01%	1107

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Montag & Associates's CYTK Position: Q4 2025 in Review

Montag & Associates sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 6 shares — an estimated $330 sold.

Montag & Associates first reported a position in CYTK in Q3 2025 and held it in 1 quarter. The position peaked at $330 in Q3 2025. 431 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

Montag & Associates reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
Montag & Associates sold 6 Cytokinetics shares in Q4 2025, an estimated $330.
Montag & Associates first reported a position in Cytokinetics in Q3 2025 and held it in 1 quarter.
Montag & Associates's Cytokinetics position peaked at $330 in Q3 2025.
431 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Montag & Associates's 13F filing for Q4 2025, filed 2 Feb 2026.